



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/903,520	07/11/2001	Avi Ashkenazi	10466/83	1093
35489	7590	05/30/2006	EXAMINER	
HELLER EHRMAN LLP 275 MIDDLEFIELD ROAD MENLO PARK, CA 94025-3506			BASI, NIRMAL SINGH	
			ART UNIT	PAPER NUMBER

1646

DATE MAILED: 05/30/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>		<b>Applicant(s)</b>	
	09/903,520		ASHKENAZI ET AL.	
	<b>Examiner</b>		<b>Art Unit</b>	
	Nirmal S. Basi		1646	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 03 March 2006.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 39-51 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 39-51 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)             | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____   | 6) <input type="checkbox"/> Other: _____                                    |

### DETAILED ACTION

1. Upon further review the finality of the rejection of the last Office action is withdrawn. The claims are newly rejected for the reasons given below.
2. Appeal Brief filed 3/03/06 has been entered.
3. Claims 1-38 are cancelled. Claims 39-51 are pending.

#### ***Claim Rejections Under 35 USC § 101 and 35 USC § 112***

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 39-51 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a credible, specific and substantial asserted utility or a well established utility. The claims are directed to the polypeptides of SEQ ID NO:290 and variants thereof, referred to in the specification as PRO335. The specification also generally asserts that all of the disclosed PRO335, based on the MLR reaction, stimulates proliferation of lymphocytes and is useful therapeutically where enhancement of an immune response is beneficial; however, this asserted use does not meet the three-pronged requirement of 35 U.S.C. 101 regarding utility, namely, that the asserted utility be credible, specific

Art Unit: 1646

and substantial. Therefore, PRO335 polypeptide and the nucleic acid encoding PRO335 polypeptide do not have any specific and substantial utility, or a well established utility, as determined according to the current Utility Examination Guidelines, Federal Register, Vol. 66, No. 4, pages 1092-1099, Friday, January 5, 2001.

Applicant asserts that Example 74, page 208 of the specification at line 27, supports utility of the claimed invention. Example 74 of the specification is stimulatory activity in a mixed lymphocyte reaction (MLR) assay. However, the ability of a protein to stimulate lymphocyte proliferation in this assay does not support a specific and substantial utility for the claimed invention. The ability to stimulate or inhibit lymphocyte proliferation in the MLR assay is an artificial *in vitro* system and does not provide for what specific conditions or for which specific diseases the claimed invention would predictably function. The assertion that the claimed invention could be useful for the treatment of conditions where the enhancement of the immune response would be beneficial is not specific since there are many such conditions, and it is not predictable of which conditions the claimed invention may function, if any. There is no information regarding what subsets of immune responses, immune cell types etc. are targeted by compounds with activities disclosed in the MLR assay.

Mixed lymphocyte culture (MLC) is a special case of antigen stimulation in which T lymphocytes respond to foreign histocompatibility antigen on unrelated lymphocytes or monocytes. MLC is a functional assay of cellular response to stimulatory determinants associated predominantly with HLA class II molecules.

Art Unit: 1646

A single genetic locus or region, known as HLA, controls the MLC reactivity. The MLC assay recognizes disparate HLA class II molecules and the resulting T-cell activation, which is thought to represent an *in vitro* model of the afferent arm of the *in vivo* allograft reaction. The degree of reactivity observed correlates with the degree of antigenic disparity between responding and stimulating cells. Briefly, when the lymphocytes of 2 HLA-disparate individuals are combined in tissue culture, the cells enlarge, synthesize DNA, and proliferate, whereas HLA-identical cells remain quiescent. Since both cells will normally proliferate, a one way test is used to monitor the response of a single responder cell by inactivating the stimulator cell by radiation or drugs in order to inhibit DNA synthesis of the stimulator cell. The proliferation is driven primarily by the differences in the class II HLA antigens between the 2 test cells (or individuals). This reaction is not predictive of general responses of the immune system because, *in vivo*, activation of a lymphocyte is controlled not only by antigen binding but also by interactions with other cells. All T cells must cooperate with antigen-presenting cells, whereas B cells and cytotoxic T cells depend on helper T lymphocytes. These interactions either require direct surface-to surface contact or are mediated by cytokines that act only over extremely short distances. Because of this interdependence, lymphocyte activation occurs commonly and efficiently in the secondary lymphoid organs, where lymphocytes, antigens, and antigen-presenting cells encounter one another at close quarters. See pages 30-31, 208-209, 246-247 of "Basic and Clinical Immunology," 1994. See also, "Manual of Clinical Laboratory Immunology," 6<sup>th</sup> Edition at pages 1164-1166.

Kahan clearly states that no *in vitro* immune assay predicts or correlates with *in vivo* immunosuppressive efficacy; there is no surrogate immune parameter as a basis of immunosuppressive efficacy and/or for dose extrapolation from *in vitro* systems to *in vivo* conditions (Cur. Opin. Immunol. 4: 553-560, 1992; see entire document, particularly page 558, column 2). Piccotti et al. (Transplantation 67: 1453-1460, 1999) demonstrate that IL-12 enhances alloantigen-specific immune function as determined by MLC, but this result *in vitro* does not result in a measurable response *in vivo* (i.e. failure to accelerate allograft rejection) (see page 1459). Campo et al. (Biological Trace Element Res. 79: 15-22, 2001) demonstrate that while zinc suppresses alloreactivity in MLC, it does not decrease T-cell proliferation *in vitro* nor produce immunosuppressive effects *in vivo*. Urso et al. (Cell. Mol. Biol. 41 suppl : s103-112, 1995, cited previously) teaches that zidovudine, which enhanced MLR response, was ultimately in fact immunosuppressive. Kond et al. (Immunology 79: 459-464, 1993, cited previously) teaches that TGF-beta has both immunosuppressive and immuno-enhancing in such *in vitro* assays, but is immunosuppressive *in vivo*. Therefore, the MLR assay, which is art recognized for determining histocompatibility, does not appear to be predictive of general immune responses *in vivo*.

Additionally, difficulties arise in quantification when using MLC as a test for T cell function due to variations in stimulator cell antigens that determine the degree of genetic disparity between stimulator and responder cells. MLC is typically used for determining histocompatibility in an individual and as a test for

Art Unit: 1646

immunocompetence of T cells in patients with immunodeficiency disorders. When running the MLC assay for determining histocompatibility for transplantation, autologous controls combining self with irradiated self are necessary to normalize the response of each cell to stimulators. Furthermore, there is known inherent variability of individual cellular responses from day to day which requires performing the entire familial MLC at one time in the case of determining histocompatibility for transplantation (page 246 in "Basic and Clinical Immunology"). When performing the MLC assay, each individual lot of a serum source should be screened for growth support capabilities and possible HLA antibodies (see page 1165 in "Manual of Clinical Laboratory Immunology"). Additionally, the screen should include a control response to a pool of allogeneic cells to measure maximum response and an autologous control to ensure low backgrounds.

Therefore, the MLC (a.k.a. MLR) assay is a measure of alloreactivity of one individual to another individual, rather than a general measure of immune function. This reactivity is governed by the antigenic disparity between the two individuals, which are being compared in the assay. Depending on the individuals being tested, the MLC may indicate stimulation if they are HLA-disparate or the MLC may indicate no stimulation if the individuals are HLA-identical. The ability of the claimed invention to stimulate proliferation in the MLC assay may not be a general stimulus to lymphocyte proliferation, but rather a reaction to one of the MHC antigens on the responder cell. The instant specification fails to provide sufficient detail of the assay, which was performed

Art Unit: 1646

and fails to provide any data whatsoever in order for one of ordinary skill in the art to evaluate the conclusion that lymphocyte proliferation was stimulated by the claimed invention. As pointed out above, there are several controls which the art recognizes as being essential for meaningful results for this assay, including autologous controls, a control to determine maximum response, screening for possible HLA antibodies and growth support capabilities. Furthermore, there is known inherent variability of individual cellular responses from day to day, which would clearly dictate the need for internal controls. The specification indicates that CD4-IgG was used as a control, but it is not clear how this would control for background stimulation or provide for a measure of maximal stimulation. Lastly, the specification fails to provide any data or evidence of the results of the assay, therefore, one of ordinary skill in the art cannot evaluate the conclusion. The specification states that "positive increases over control are considered positive", however, this does not indicate that statistical significance must occur for determination of a positive result in the assay. In conclusion, the results of the MLC (a.k.a. MLR) assay do not support a specific and substantial utility for the claimed invention because the assay is not predictive of immune response in general, and one of ordinary skill in the art would not expect a stimulatory effect in the MLC assay to correlate to a general stimulatory effect on the immune system, absent evidence to the contrary.

5. Claims 39-51 are also rejected under 35 U.S.C. 112, first paragraph.



Art Unit: 1646

Specifically, since the claimed invention is not supported by either a credible, specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

6. The rejection of claims 39-51 under 35 U.S.C. 112, first paragraph, as lacking enablement is maintained for reasons of record in the office actions of 8/11/05, 12/23/04, 4/28/04 and 11/26/03.

Applicants argue that the MLR assay is a well accepted and useful assay for identifying immunostimulants and is a widely used proliferative assay of T-cell function and can identify agents that can boost the immune system. Dr. Fong points to IL-12 as such a stimulant and states that a PRO polypeptide that stimulates T-cell proliferation with an activity "at least 180% of control" would find practical utility as an immune stimulant. Applicants submit that PRO335, contributes to stimulating the cellular responses (cellular immunity) rather than the humoral responses, of the immune system and therefore, is not directed to any "particular antigen". Applicant further argues the MLR assay is useful for detecting immunostimulatory activities of molecules like PRO335.

Applicants' arguments have been fully considered but have not been found to be persuasive. No "particular antigen" is identified in the specification; there is no guidance as to how PRO335 could be used to boost the response to any antigen. Current Protocols in Immunology states on p. 3.12.11 that the MLR "only detects dividing cells instead of measuring true effector T-cell function" and that it is "not clear which T cell function is measured in proliferative assays", and

Art Unit: 1646

further that "the proliferative response should be used solely as a general indicators of T cell reactivity". Data obtained might variously reflect proliferation of CTL, lymphokine producing T cells, or non-activated bystander cells and will be severely affected by the function of non-T cells. Differences in responsiveness in a proliferative assay in part reflect differences in IL-2 production, according to Current Protocols in Immunology. As has been stated previously, the MLR measures the reactivity of one individual to another and is, as Current Protocols in Immunology states, highly variable. Current Protocols in Immunology in fact describes many variables that must be controlled for. In the instant application, no such controls, such as for maximum response or for the inherent variability of individual responses, are provided. There is no indication of the statistical significance of the results. There are no autologous controls. No correlation is provided to any particular *in vivo* function; there is no guidance to indicate that PRO335 could be used to any therapeutic effect for the treatment of diseases such as cancer or HIV. The references cited by Applicant fail to provide compensatory guidance. Steinman and Thurner et al. (see previous office action) address the utility of dendritic cells but not of a stimulatory MLR. Gubler see previous office action) describes the identification of the molecule IL-12 but uses the MLR merely to compare activities, not as the basis for describing a molecule as a therapeutically useful immunostimulant. The subsequent research of Peterson et al. (see previous office action) was clearly required to suggest that the molecule could be used in this fashion. Thus, without further

Art Unit: 1646

guidance correlating the observed stimulatory activity to a particular, useful property, it would require undue experimentation to use PRO335.

7. Claims 39-43, 50 and 51 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims are drawn to polypeptide having at least 80%, 85%, 90%, 95% or 99% sequence identity with a particular disclosed sequence. The claims do not require that the polynucleotide or encoded polypeptide possess a specific function associated with PRO335, only that the polypeptide encoded by said polynucleotide be immunostimulant. All polypeptides can be considered immunostimulants. Apart from the polynucleotide of SEQ ID NO:289 encoding the polypeptide of 290, the particular conserved structures or other distinguishing structural features critical for a specific activity of PRO 335 are not disclosed. Thus, the claims are drawn to genus of polypeptides that is defined only by sequence identity and general activity (applicable to many other polynucleotides) and no specific activity that can be associated with any specific domains of PRO335.

To provide evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function

Art Unit: 1646

correlation, methods of making the claimed product, or any combination thereof. In this case, the only factor present in the claim is a partial structure in the form of a recitation of percent identity. There is not even identification of any particular portion of the structure that must be conserved for function. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus. Naming a type of material generically known to exist, in the absence of knowledge as to what that material consists of, is not a description of that material. When one is unable to envision the detailed constitution of a complex chemical compound having a particular function, such as a polypeptide, so as to distinguish it from other materials, as well as a method for obtaining it, conception has not been achieved until reduction to practice has occurred, i.e., until after the polypeptide has been isolated. Thus, claiming all polypeptides that achieves a result without defining what means will do so is not in compliance with the description requirement. Rather, it is an attempt to preempt the future before it has arrived. The claims recite a broad arbitrary structural relationship between the claimed polypeptides sequences, either in terms of its nucleotide sequence of PRO335 or the polypeptide encoded, and the single disclosed species of nucleotide sequence and amino acid sequence, respectively. The claims are not even directed to polypeptides, which have a specific function associated with PRO335, only a general function associated with all proteins. Further, if applicant argues PRO335 works in the MLR assay by immunostimulation, it must be noted that the immunostimulation activity is not considered an activity that that has

Art Unit: 1646

been correlated with a specific structure contained in PRO335 as it pertains to said assay. Further non-functional or functionally unrelated proteins to PRO335 are encompassed by the claims. The recited structural relationships are arbitrary since neither the specification nor the prior art discloses any definitive relationship between protein function and % identity or homology at either the nucleotide or amino acid level; and the specification does not describe a single species of polypeptide that is a functional protein that is not 100% identical to the recited polypeptide, or encoding nucleic acid that is not 100% identical to SEQ ID NO:289.

While one of skill in the art can readily envision numerable species of polypeptide sequences that are at least a given % identity to a reference polypeptide, one cannot envision which of these polypeptides has a specific activity of the protein of SEQ ID NO:290. The fact remains that the actual amino acid sequences of such a polypeptide *cannot* be envisioned any better when the possible choices are narrowed from all possible sequences to all possible sequences with an arbitrary structural relationship with a known functional sequence. For example, if one skilled in the art were to make a synthetic nucleotide sequence that encoded a polypeptide with 90% identity to the reference amino acid sequence, he would be no more able to say whether it encoded a functional polypeptide than if the nucleotide sequence encoded a polypeptide that was only 10% identical to the reference polypeptide sequence. Nor would he be able to say whether the sequence existed in nature.

Art Unit: 1646

To put the situation in perspective, the number of possible amino acid sequences of 100 amino acids in length is  $20^{100}$  (approx.  $10^{130}$ ) and the number of possible nucleotide sequences of 300 nucleotides in length is  $4^{300}$  (approx.  $4 \times 10^{180}$ ). The number of possible nucleotide or amino acid sequences that are of a given %identity relative to a reference sequence, where all differences between the possible sequences and the reference sequence are substitutions, can be calculated by the following formula:

$$N = XL + X^2L(L-1)/2! + X^3L(L-1)(L-2)/3! + \dots + X^{n-1}L(L-1)(L-2)\dots(L-(n-2))/(n-1)! + X^nL(L-1)(L-2)\dots(L-(n-1))/n!$$

where N is the number of possible sequences, X is the number of different residues that can be substituted for a residue in the reference sequence, L is the length of the reference sequence, n is the maximum number of residues that can be inserted, deleted or substituted relative to the reference sequence at a given % identity. For a nucleotide sequence, X is 3 (alternate nucleotides); for an amino acid sequence, X is 19 (alternate amino acids).

For a 100 amino acid sequence that is at least 90% identical to a reference sequence of 100 amino acids, the number of possible sequences having 9 amino acid substitutions relative to the reference (the penultimate term of the formula) is approximately  $6 \times 10^{23}$ . Whereas the number of possible sequences having 10 amino acid substitutions relative to the reference (the final term of the formula) is approximately  $1.1 \times 10^{26}$ . So the last term is approximately equal to N, i.e. the preceding terms contribute little to the total. It can also be shown that N can be approximated by the formula  $X^nL^n/n!$ , where  $n \ll L$ . Using

Art Unit: 1646

this formula to approximate N in this example gives a value of  $1.7 \times 10^{26}$ . For a 300 nucleotide reference sequence, the number of possible 300 nucleotide sequences that are at least 90% identical to the reference is approximately  $1.6 \times 10^{56}$ .

In the present case, the reference amino acid sequence, SEQ ID NO:290 is 1059 amino acids long, and the reference nucleotide sequence, SEQ ID NO:289 is 3662 nucleotides long. Using the approximation formula, the number of possible amino acid sequences and nucleotide sequences that are at least e.g. 80% identical to the reference amino acid sequence or nucleotide sequence, would be much larger than  $6 \times 10^{23}$  and  $1.6 \times 10^{56}$ , respectively. While limiting the scope of potential sequences to those that are at least e.g. 80% identical to a reference greatly reduces the number of potential sequences to test, it does not do so in any meaningful way. All of these values greatly exceed the estimated number of atoms in the universe ( $10^{70}$  to  $10^{90}$ ). Thus, limiting the claims by the recited structural relationships merely reduces the degree of impossibility of making and testing sequences for those, which encode a functional protein encompassed by the claims. Therefore, inclusion of the structural relationships in the claim does not distinguish the instant fact situation from those reviewed in *Amgen, Fiers, and Regents of the Univ. Calif.*

The specification does not provide any information on what amino acid residues are necessary and sufficient for a functional activity. The specification also provides no teachings on what amino acid sequence modifications, e.g. insertions, deletions and substitutions, would be permissible in an active PRO335

Art Unit: 1646

polypeptide that would improve or at least would not interfere with the biological activity or structural features necessary for the biological activity and stability of the protein. Since there are no other examples of proteins that have structural homology with SEQ ID NO:335 to predict function or functional domains required for activity, it is not possible to even guess at the amino acid residues, which are critical to its structure or function based on sequence conservation. Therefore one cannot predict variant amino acid sequences for a biologically active polypeptide. Rather one must engage in case to case painstaking experimental study to determine active PRO335 variants. Consequently, excessive trial and error experimentation would have been required to identify the necessary nucleic acid sequence derivatives encoding a biologically active PRO335 with an amino acid sequence differing from SEQ ID NO:290 since the amino acid sequence of such polypeptides could not be predicted.

The specification discloses only one putative amino acid sequences, SEQ ID NO:290, for a polypeptide having the necessary properties for the disclosed uses, and provides no guidance on obtaining functional polypeptide variants of SEQ ID NO:290 encoded by the nucleic acid of SEQ ID NO:289, which would be suitable.

*Vas-Cath Inc. v. Mahurkar*, 19USPQ2d 1111 , clearly states that applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in



Art Unit: 1646

the ad to recognize that (he or she) invented what is claimed." (See *Vas-Cath* at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of polynucleotides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF'S were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Therefore, only isolated polynucleotides encoding polypeptides comprising the amino acid sequence set forth in SEQ ID NO: 289 but not the full breadth of the claims meets the written description provision of 35 U.S.C. 112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. 112 is severable from its enablement provision (see page 1 115).

8. No claim is allowed.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nirmal S. Basi whose telephone number is 571-272-0868. The examiner can normally be reached on 9:00 AM-5:30 PM.

Art Unit: 1646

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Nirmal S. Basi

Art Unit 1646

5/26/06

  


**GARY B. NICKOL, PH.D.**  
**PRIMARY EXAMINER**